Injection site fibroblasts acquire antigen-presenting cell properties and modulate mRNA-LNP immune responses
This study reveals that mRNA-LNP vaccines induce tissue-resident fibroblasts at the injection site to acquire antigen-presenting cell properties, demonstrating that LNP composition directly shapes stromal cell function to modulate global immune responses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
When a vaccine is injected into a muscle, the body does not simply wait for the medicine to work. Instead, the injection site becomes a bustling hub of activity where the immune system gathers to learn how to fight a threat. For years, scientists understood that specialized immune cells, known as antigen-presenting cells, act as the primary teachers in this process. These cells pick up pieces of the vaccine, travel to the lymph nodes, and show the information to T cells, which then launch a targeted defense. This system relies on a clear division of labor: immune cells do the teaching, while other cells in the muscle, such as fibroblasts, were thought to be passive structural workers, merely providing the scaffolding that holds the tissue together.
However, the landscape of vaccine science has shifted dramatically with the arrival of messenger RNA, or mRNA, vaccines. These vaccines deliver genetic instructions into cells, telling them to build a specific protein that trains the immune system. While this technology has proven incredibly effective, the exact details of how the body responds at the injection site remain only partially understood. Researchers have long wondered if the cells at the injection site are merely bystanders or if they play a more active role in shaping the immune response. Understanding these local interactions is crucial, not just for improving vaccines against infectious diseases, but for refining how we deliver genetic therapies and other treatments that rely on similar technology.
A team of researchers at Sanofi and their collaborators set out to map this hidden activity in detail. They injected mice with mRNA vaccines designed to carry instructions for a flu virus protein. By taking samples from the muscle, lymph nodes, spleen, and blood at different times after the injection, they created a high-resolution map of how genes were turned on and off throughout the body. Their analysis confirmed that the muscle at the injection site was indeed the most active location, showing a massive surge in genetic activity within the first few days. This local response was so intense that it drew in large numbers of immune cells, including monocytes and dendritic cells, which began their work of capturing the vaccine material and preparing to alert the rest of the immune system.
The most surprising discovery emerged when the researchers looked closely at the non-immune cells in the muscle. They found that fibroblasts, the cells that provide structure to the tissue, were not just sitting idle. Instead, these fibroblasts were directly taking up the vaccine instructions and building the flu protein themselves. Even more remarkably, these structural cells began to display the same molecular tools used by professional immune teachers. They started expressing proteins on their surface that are typically reserved for antigen-presenting cells, effectively transforming into temporary instructors capable of showing the flu protein to T cells. This was not a random side effect; the researchers observed that the specific design of the vaccine's delivery vehicle influenced how strongly these fibroblasts responded, suggesting that scientists could tune the vaccine to better engage these cells.
To confirm that this transformation was real and functional, the team moved beyond the mouse model and tested human cells in the laboratory. They took human fibroblasts and exposed them to the same mRNA vaccine technology. Just as in the mice, these human cells began to produce the flu protein and displayed the necessary markers to present it to T cells. When the researchers mixed these modified fibroblasts with human immune cells, the T cells became activated, proving that the fibroblasts were successfully performing the job of an immune teacher. This finding suggests that the ability of fibroblasts to present antigens is a conserved feature across species, meaning it is a fundamental part of how the body reacts to this type of vaccine.
The study also revealed that the composition of the vaccine's delivery vehicle, specifically the helper lipids used to package the genetic material, could change which cells received the instructions. By altering these lipids, the researchers could shift the focus of the response, causing more fibroblasts to take up the vaccine and express the antigen. This indicates that the design of the vaccine itself can directly shape the behavior of the tissue environment. Rather than viewing the injection site as a passive location where a vaccine is simply deposited, the research shows it is a dynamic environment where structural cells and immune cells work together. The fibroblasts, once thought to be mere background players, are active participants that help drive the immune response, offering a new avenue for scientists to optimize how vaccines and therapies work in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.